Published in
Taylor and Francis Group, Expert Opinion on Drug Safety, 4(20), p. 411-426, 2021
DOI: 10.1080/14740338.2021.1890023
Links
Tools
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 